IRIS
PIERANTOZZI, MARIANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 48.361
EU - Europa 4.723
AS - Asia 1.536
Continente sconosciuto - Info sul continente non disponibili 22
SA - Sud America 21
OC - Oceania 7
AF - Africa 3
Totale 54.673
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 48.336
IT - Italia 1.859
SG - Singapore 920
UA - Ucraina 632
DE - Germania 568
IE - Irlanda 516
CN - Cina 399
FR - Francia 312
GB - Regno Unito 183
RU - Federazione Russa 147
FI - Finlandia 144
KR - Corea 137
SE - Svezia 126
PL - Polonia 118
BE - Belgio 27
CA - Canada 22
EU - Europa 21
GR - Grecia 15
IN - India 15
JP - Giappone 15
CZ - Repubblica Ceca 14
VN - Vietnam 13
BR - Brasile 12
NL - Olanda 11
RO - Romania 11
CH - Svizzera 9
KG - Kirghizistan 8
AU - Australia 6
CL - Cile 5
ES - Italia 5
PT - Portogallo 5
TR - Turchia 5
UZ - Uzbekistan 5
AL - Albania 4
AT - Austria 4
HK - Hong Kong 4
SK - Slovacchia (Repubblica Slovacca) 4
IL - Israele 3
AZ - Azerbaigian 2
DK - Danimarca 2
DM - Dominica 2
EG - Egitto 2
IQ - Iraq 2
MY - Malesia 2
PE - Perù 2
SM - San Marino 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
BY - Bielorussia 1
CO - Colombia 1
HU - Ungheria 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
MK - Macedonia 1
MX - Messico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
TN - Tunisia 1
TW - Taiwan 1
Totale 54.673
Salva come PNG Salva come JPEG
Città #
Woodbridge 13.874
Wilmington 13.213
Houston 12.126
Fairfield 1.767
Ann Arbor 1.083
Singapore 814
Ashburn 798
Seattle 623
Cambridge 608
Chandler 607
Jacksonville 577
Dublin 478
Medford 365
Rome 263
Santa Clara 240
Dearborn 230
Beijing 185
Milan 170
Lawrence 169
New York 123
Kraków 111
San Diego 97
Menlo Park 70
Moscow 68
Turin 42
Verona 42
London 40
Norwalk 39
Mülheim 36
Zhengzhou 36
Durham 35
Falls Church 33
Redwood City 32
Naples 31
Florence 27
Munich 27
Shanghai 27
Brussels 26
Helsinki 25
Mountain View 24
Palo Alto 24
Genoa 22
Sassari 22
Bologna 20
Nanjing 20
San Jose 20
Seoul 20
Boardman 19
Council Bluffs 19
University Park 19
St Louis 18
Hefei 17
Padova 17
Kunming 16
Phoenix 15
Toronto 15
Brno 13
Catania 13
Nürnberg 13
Modena 12
Reggio Calabria 12
Bari 11
Los Angeles 11
Palermo 11
Pisa 11
Redmond 11
Saint Petersburg 11
Trento 11
Engelhard 10
Garden City 10
Hounslow 10
Kilburn 10
Mcallen 10
Pavia 10
Athens 9
Bergamo 9
Creede 9
Wuhan 9
Del Norte 8
Dong Ket 8
Nuremberg 8
Reggio Emilia 8
Chengdu 7
Parma 7
Pune 7
Ravenna 7
Altamura 6
Brescia 6
Caserta 6
Changsha 6
Detroit 6
Frankfurt am Main 6
Guangzhou 6
Islington 6
Jinan 6
Messina 6
Partinico 6
Pescara 6
Sale Marasino 6
San Zeno Naviglio 6
Totale 49.864
Salva come PNG Salva come JPEG
Nome #
Quality of life in Parkinson’s disease: Italian validation of the Parkinson’s Disease Questionnaire (PDQ-39-IT) 1.404
malattia di alzheimer e altre demenze diagnosi e terapia integrata. 697
CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia 441
Spontaneous sleep modulates the firing pattern of Parkinsonian subthalamic nucleus 440
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. 439
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis 433
Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a natural population of cognitive intact Parkinson's Disease patients. 430
Cortical hyperexcitability in post-traumatic stress disorder secondary to minor accidental head trauma: a neurophysiologic study 429
Autonomic Function Tests and MIBG in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms 427
SEPs N30 amplitude in Parkinson's disease and in pharmacologically induced rigidity: relationship with the clinical status 426
Electrophysiological evidence for visuocognitive dysfunction in younger non Caucasian patients with Parkinson's disease 424
High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients 423
Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia 420
The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson's disease 418
Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease 418
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 417
Curariform peripheral block of muscular tone selectively increases precentral N30 somatosensory evoked potentials component. A pharmacological study carried out on healthy subjects and parkinsonian syndromes 416
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease 415
Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients 414
Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment 414
Perfusion-weighted dynamic susceptibility (DSC) MRI: basal ganglia hemodynamic changes after apomorphine in Parkinson's disease 412
Strength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process 408
Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease 408
Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson's disease 407
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature 406
Deep brain stimulation of CM/PF of thalamus could be the new elective target for tremor in advanced Parkinson's Disease? 406
Optic Nerve dysfunction in obstructive sleep apnea: An electrophysiological study 406
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome 404
Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart 402
The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus 402
Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study. 401
Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study 400
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 399
Deep brain stimulation of pedunculopontine tegmental nucleus: role in sleep modulation in advanced Parkinson disease patients: one-year follow-up. 398
123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study 398
Therapy for dyskinesias in Parkinson’s disease patients 396
Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease 395
Restless legs syndrome and poliomyelitis: New evidences of an old observation? 395
May a suspicious psychiatric disorder hide sporadic hemiplegic migraine? Genetic test as prompting factor for diagnosis 393
Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease 392
Bilateral GPi DBS is useful to reduce abnormal involuntary movements in advanced Parkinson's disease patients, but its action is related to modality and site of stimulation 391
Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials 391
Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT 391
Pedunculopontine nucleus stimulation influences REM sleep in Parkinson's disease 389
Deep brain stimulation of both subthalamic nucleus and internal globus pallidus restores intracortical inhibition in Parkinson's disease paralleling apomorphine effects: a paired magnetic stimulation study 389
Pathological gambling from dopamine agonist and deep brain stimulation of the nucleus tegmenti pedunculopontine 389
The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease. 388
An electrophysiological study of D2 dopaminergic actions in normal human retina: a tool in Parkinson's disease 387
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations 387
Effect of Vigabatrin on motor responses to transcranial magnetic stimulation: An effective tool to investigate in vivo GABAergic cortical inhibition in humans 382
Involvement of Subcortical Brain Structures During Olfactory Stimulation in Multiple Chemical Sensitivity 381
Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients 378
Effect of apomorphine on cortical inhibition in Parkinson's disease patients: a transcranial magnetic stimulation study 378
Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients - An ambulatory polysomnographic study 377
The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease 377
Age and stage dependency of P300 latency alterations in non-demented Parkinson's disease patients without therapy 377
A mixed D1 and D2 antagonist does not replay pattern electroretinogram alterations observed with a selective D2 antagonist in normal humans: relationship with Parkinson's disease pattern electroretinogram alterations 377
Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients 376
Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: lack of clear evidence for the 'indirect pathway' 368
Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain 366
Motor and non-motor effects of PPN-DBS in PD patients: insights from intra-operative electrophysiology 365
Emotional processing in Parkinson's disease. A study using functional transcranial doppler sonography 365
Catecholamine-based treatment in AD patients: expectations and delusions 365
CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD 364
Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder 364
Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: molecular imaging with ¹²³I-MIBG. 363
123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms 363
Does pattern electroretinogram spatial tuning alteration in Parkinson's disease depend on motor disturbances or retinal dopaminergic loss? 362
Alexithymia is a non-motor symptom of Parkinson disease 361
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. 360
Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease 358
Deep brain stimulation in Parkinson's disease patients: biochemical evidence 357
The effect of deep brain stimulation on the frontal N30 component of somatosensory evoked potentials in advanced Parkinson's disease patients 356
Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in parkinsonian patients 355
Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer’s disease 354
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations.(Reply from the authors) 353
CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment 352
The visuo-cognitive and motor effect of amantadine in non-Caucasian patients with Parkinson's disease. A clinical and electrophysiological study 352
Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinson's disease 351
Long term effects of Helicobacter pylori eradication on L-dopa absorption in Parkinson's disease 351
Neurological complications of pregnancy 351
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids 349
N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study 349
Deep brain stimulation of the pedunculopontine tegmentum and subthalamic nucleus: effects on gait in Parkinson's disease 347
Deep brain stimulation of pedunculopontine tegmental nucleus (PPTg) promotes cognitive and metabolic changes: a target-specific effect or response to a low-frequency pattern of stimulation? 343
Increasing doses of l-sulpiride reveal dose- and spatial frequency-dependent effects of D2 selective blockade in the human electroretinogram 343
L-dopa modulates motor cortex excitability in Alzheimer's disease patients 342
P3 components evoked by unilateral and bilateral somatosensory stimulation: normative data for the study of neglect syndrome 342
Reduced GABA Content in the Motor Thalamus during effective deep brain stimulation of the subthalamic nucleus 340
Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. 338
Deep brain stimulation (DBS) attentional effects parallel those of l-dopa treatment 337
A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease 336
Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients 333
Does 123I-MIBG scintigraphy really assist the diagnosis of Parkinson's disease? 332
Pedunculopontine nucleus deep brain stimulation changes spinal cord excitability in Parkinson's disease patients 328
Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease 328
When cognitive decline and depression coexist in the elderly: CSF biomarkers analysis can differentiate Alzheimer's disease from late-life depression 328
Multi-target strategy for Parkinsonian patients: the role of deep brain stimulation in the centromedian-parafascicularis complex. 327
Antiparkinsonian and anti-levodopa-induced dyskinesia effects obtained by stimulating the same site within the GPi in PD 327
Grammar improvement following deep brain stimulation of the subthalamic and the pedunculopontine nuclei in advanced Parkinson's disease: A pilot study 325
Totale 39.328
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.653
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.653
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202011.107 0 0 0 1.380 1.225 1.511 1.212 1.309 1.310 1.196 857 1.107
2020/20218.487 985 1.094 958 1.071 837 880 1.041 782 214 170 371 84
2021/20222.000 64 249 99 74 69 131 319 90 116 133 149 507
2022/20231.951 211 130 71 211 142 467 183 106 152 36 146 96
2023/20241.722 126 57 113 105 151 205 147 256 69 136 104 253
2024/20252.055 221 1.148 618 68 0 0 0 0 0 0 0 0
Totale 55.491